Biotechnology Sector Sentiment & Funding: As a clinical-stage pharmaceutical company, Amylyx Pharmaceuticals' ability to fund its research, development, and clinical trials is highly dependent on investor sentiment towards the biotechnology sector and the availability of capital. A risk-off market environment or rising interest rates could make it more challenging to raise necessary funds.

Regulatory Environment & FDA Approvals: The success of Amylyx's drug candidates, such as avexitide for post-bariatric hypoglycemia and AMX0114 for ALS, hinges significantly on positive outcomes from clinical trials and subsequent regulatory approvals from bodies like the U.S. FDA. Any changes in regulatory policies or delays in approval processes could substantially impact the stock.

Global Economic Conditions & Healthcare Spending: Broader economic trends, including global growth forecasts and healthcare spending policies, can indirectly affect Amylyx. While not directly exposed to commodity price fluctuations, a general economic slowdown, such as that suggested by IMF downgrades amid the Middle East conflict, could reduce investor appetite for higher-risk growth stocks in the biotech sector and potentially influence future healthcare budgeting and reimbursement landscapes.